Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Will The Human Immunodeficiency Virus Therapeutics Market Valuation Change Between Now And 2029?

The market size for human immunodeficiency virus therapeutics has seen substantial growth in the past few years. Projected growth indicates an increase from $14.11 billion in 2024 to $14.9 billion in 2025, boasting a compound annual growth rate (CAGR) of 5.6%. This historic upsurge is accredited to the increase in HIV cases, enhancement in awareness programs, growth in diagnostic testing, an increased penetration of generic drugs, and the expansion of healthcare infrastructure.

The market size for therapeutics related to the human immunodeficiency virus is projected to experience robust growth in the upcoming years, reaching $18.44 billion by 2029 with a compound annual growth rate (CAGR) of 5.5%. This growth during the predictive period can be linked to factors such as an increasing number of HIV patients, escalated HIV testing, more voluntary testing, a rise in unsafe sex practices, and broader government initiatives. Major shifts anticipated during this forecast period encompass advancements in technology, drug discovery powered by Artificial Intelligence, the rise of long-acting injectable therapies, integration of telemedicine, and gene therapy using CRISPR techniques.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23419&type=smp

What Growth-Enabling Forces Are Impacting The Human Immunodeficiency Virus Therapeutics Market?

The rising frequency of unprotected sexual activities is anticipated to fuel the expansion of the human immunodeficiency virus therapeutics market. Unprotected sexual activities increase the chances of acquiring sexually transmitted infections (STIs) and unintentional pregnancies due to the lack of barrier protection. Inadequate comprehensive sex education results in limited knowledge about safe practices, leading to increased risk-taking behavior among young people. HIV therapeutics work to decrease the risk of HIV transmission from unprotected sex by suppressing the viral load to negligible levels, hence stopping further transmission of the infection. Periodic surveys illustrate this growing concern, for example, in November 2024, the Centers for Disease Control and Prevention, a US-based government agency, revealed that 32% of U.S. high school students reported having had sexual intercourse and an alarming 48% confessed to not using a condom during their most recent sexual experience. Hence, the escalating prevalence of unprotected sexual activities is propelling the growth of the human immunodeficiency virus therapeutics market.

What Are The Main Segment Classifications In The Human Immunodeficiency Virus Therapeutics Market?

The human immunodeficiency virus therapeuticsmarket covered in this report is segmented –

1) By Drug Type: Branded Drugs; Generic Drugs

2) By Drug Class: Nucleoside-Analog Reverse Transcriptase Inhibitors (Nrtis); Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis); Entry And Fusion Inhibitors; Protease Inhibitors (Pis); Integrase Inhibitors; Coreceptor Antagonists

3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies

4) By End-user: Hospitals And Clinics; Specialty Centers

Subsegments:

1) By Branded Drugs: Biktarvy; Triumeq; Genvoya; Juluca; Dovato; Isentress; Prezista

2) By Generic Drugs: Tenofovir Disoproxil Fumarate (TDF); Lamivudine; Efavirenz; Zidovudine; Nevirapine; Abacavir; Ritonavir

Which Emerging Trends Are Reshaping The Human Immunodeficiency Virus Therapeutics Market Landscape?

Leading businesses in the human immunodeficiency virus (HIV) therapeutics market are turning their attention towards the creation of novel therapies, such as combined therapy, with the intent to advance treatment effectiveness, diminish drug resistance, and boost patient compliance. The methodology of combination therapy includes the incorporation of two or more therapeutic elements, comprising drugs or additional treatments, to manage a solitary disease or state. This methodology improves therapeutic efficiency, decreases side effects, and reduces the probability of drug resistance. For example, in December 2022, Gilead Sciences Inc., a biopharmaceutical enterprise situated in the US, attained endorsement from the U.S. Food and Drug Administration (FDA) for Sunlenca (lenacapavir). This therapy, used synergistically with other antiretroviral drugs, was developed for adults having multi-drug-resistant HIV-1. Sunlenca is distinguished for being first and sole HIV cure based on a capsid inhibitor, presenting a twice-a-year dosing alternative for patients who have experienced comprehensive therapy. The endorsement is bolstered by the CAPELLA trial which exhibited high rates of enduring virologic repression. Sunlenca, with its inventive mechanism of function and long-lasting formulation, is projected to assume a significant function in forthcoming HIV therapy and prevention approaches.

Which Firms Are Driving Innovation Within The Human Immunodeficiency Virus Therapeutics Market?

Major companies operating in the human immunodeficiency virus therapeutics market are Pfizer Inc., Johnson & Johnson, F Hoffmann La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol Myers Squibb Company (BMS), Novartis International AG, GlaxoSmithKline plc (GSK), Gilead Sciences Inc., Moderna Inc., BioNTech SE, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Aurobindo Pharma Limited, Cipla Limited, Hetero Labs Limited, Gilead Sciences Inc. / Kite Pharma Inc. (for CAR T HIV cure research), Vir Biotechnology Inc., Theratechnologies Inc., CytoDyn Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/human-immunodeficiency-virus-therapeutics-global-market-report

What Are The Emerging Regional Trends Driving The Human Immunodeficiency Virus Therapeutics Market?

North America was the largest region in the human immunodeficiency virus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human immunodeficiency virus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=23419&type=smp

Browse Through More Reports Similar to the Global Human Immunodeficiency Virus Therapeutics Market 2025, By The Business Research Company

Antivirus Software Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antivirus-software-global-market-report

Coronavirus Covid 19 Current Therapy Market 2025

https://www.thebusinessresearchcompany.com/report/coronavirus-covid-19-current-therapy-market

Virus Filtration Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/virus-filtration-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model